Cox, Jiayi
Sherva, Richard
Wetherill, Leah
Foroud, Tatiana https://orcid.org/0000-0002-5549-2212
Edenberg, Howard J. https://orcid.org/0000-0003-0344-9690
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
Farrer, Lindsay A. https://orcid.org/0000-0001-5533-4225
Article History
Received: 7 October 2020
Revised: 4 May 2021
Accepted: 13 May 2021
First Online: 29 June 2021
Conflict of interest
: R.K. is a member of an advisory board for Dicerna Pharmaceuticals and of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which in the past 3 years was sponsored by AbbVie, Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, and Pfizer. R.K. and J.G. are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. Other authors do not report any conflicts of interest.